The effectiveness of molnupiravir has been a topic of discussion, with initial findings suggesting a 50% reduction in hospitalizations, later revised to 30%. While this pill offers easier access compared to monoclonal antibodies, which are 70-85% effective but costly and complex to administer, the need for more effective antiviral options remains critical in the fight against Covid.
